Endocannabinoids are lipid mediators with protective effects in many diseases of the nervous system. We have studied the modulation of the endocannabinoid system after a spinal cord contusion in rats. In early stages, lesion induced increases of anandamide and palmitoylethanolamide (PEA) levels, an upregulation of the synthesizing enzyme NAPE-phospholipase D and a downregulation of the degradative enzyme FAAH. In delayed stages, lesion induced increases in 2-arachidonoylglycerol and a strong upregulation of the synthesizing enzyme DAGL-α, that is expressed by neurons, astrocytes and immune infiltrates. The degradative enzyme MAGL was also moderately increased but only 7 days after the lesion. We have studied the cellular targets for the newly formed endocannabinoids using RT-PCR and immunohistochemistry against CB 1 and CB 2 receptors. We observed that CB 1 was constitutively expressed by neurons and oligodendrocytes and induced in reactive astrocytes. CB 2 receptor was strongly upregulated after lesion, and mostly expressed by immune infiltrates and astrocytes. The endocannabinoid system may represent an interesting target for new therapeutical approaches to spinal cord injury.
Introduction
Most human spinal cord injuries (SCIs) result from accidents that fracture or dislocate the spinal column. Some of them produce penetrating wounds but many result in transient compression or contusion of the spine. Spinal lesions are frequently suffered by young healthy people and constitute a very important physical and psychological burden and an elevated and sustained economical cost for the individuals, their families and their communities (Ackery et al., 2004; Ho et al., 2007) . There are no current treatments for spinal cord injury. Surgery, physical therapy and rehabilitation are still the most effective strategies to improve the quality of life and autonomy of injured patients (Baptiste and Fehlings, 2007; Schwab et al., 2006; Thuret et al., 2006) . This situation contrasts with the variety of approaches employed in basic research to get any improvement in animal motor or sensitive outcomes after experimental SCI, including cell transplantations, pharmacology, electrotherapy, blockage of myelin inhibitors or combined therapies (Baptiste and Fehlings, 2007; Bradbury and McMahon, 2006; Reier, 2004; Schwab et al., 2006; Thuret et al., 2006) . This scenery, that frequently shows discrepancies between the treatments in the laboratories and the results obtained in clinical trials, can have many interpretations, like species differences or inadequate evaluation methods (Schwab et al., 2006) . It is also probable that we still ignore key players involved in the development of the damage and the tissue response to the insult.
Endocannabinoids are lipid mediators formed from plasma membrane precursors that bind the cannabinoid receptors CB 1 or CB 2 . During the last years, the endocannabinoid system has attracted the attention of researchers working in neural damage and repair and is being considered a promising target for the development of new therapies (Di Marzo, 2008; Pacher et al., 2006) . This increasing interest is supported by evidence showing that the endocannabinoids 2-arachidonoylglycerol (2-AG) and arachidonoyl ethanolamide or anandamide (AEA) are produced "on demand" following cerebral ischemia (Amantea et al., 2007; Muthian et al., 2004) , excitotoxic damage (Hansen et al., 2001; Marsicano et al., 2003) and traumatic brain injury (Panikashvili et al., 2001 ) and have been shown to act as neuroprotective and immunomodulatory mediators after lesions of the nervous system (Arevalo-Martin et al., 2008; Di Marzo, 2008; Klein, 2005; Mechoulam, 2002; Pacher et al., 2006) . Moreover, some Neurobiology of Disease 33 (2009) 57-71 
